Temozolomide

Name: Temozolomide
Brand: Selleck Chemicals
SKU: S1237
Rating: 5 (98 reviews)

For research use only.

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856,TMZ

98 publications

CAS No. 85622-93-1

Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

Selleck's Temozolomide has been cited by 98 publications

Nature, 2020, 580(7804):517-523.

PubMed: 32322066 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

Nat Commun, 2020, 11(1):550

PubMed: 31992716 ( click the link to review the publication )

J Clin Invest, 2020, 139542

PubMed: 33332283 ( click the link to review the publication )

J Thorac Oncol, 2020, 10.1016/j.jtho.2020.01.012

PubMed: 32004714 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2585.2020

PubMed: 33229458 ( click the link to review the publication )

Oncogene, 2020, 5

PubMed: 32372061 ( click the link to review the publication )

EBioMedicine, 2020, 59:102971

PubMed: 32846370 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):890

PubMed: 33087705 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 22;5(1):44

PubMed: 32317623 ( click the link to review the publication )

Cell Chem Biol, 2020, S2451-9456(20)30384-6

PubMed: 33113406 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(10):2001-2011

PubMed: 32737157 ( click the link to review the publication )

Aging (Albany NY), 2020, 29;12(2):1685-1703

PubMed: 32003751 ( click the link to review the publication )

Neuroendocrinology, 2020, 3

PubMed: 32241015 ( click the link to review the publication )

Mater Sci Eng C Mater Biol Appl, 2020, 108:110191

PubMed: 31923988 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15114

PubMed: 32150671 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(21)E8353

PubMed: 33171763 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3836

PubMed: 32123273 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Neurosci, 2020, 14:598266

PubMed: 33328869 ( click the link to review the publication )

Fluids Barriers CNS, 2020, 2;17(1):37

PubMed: 32487241 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(7):1659-1670

PubMed: 32279088 ( click the link to review the publication )

Transl Oncol, 2020, 13(1):70-78

PubMed: 31810002 ( click the link to review the publication )
PLoS One, 2020, 22;15(4):e0231470

PubMed: 32320427 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cancer Res, 2020, canres.132.2020

PubMed: 32680921 ( click the link to review the publication )

Cell Signal, 2020, 71:109598

PubMed: 32165236 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):137

PubMed: 32677981 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:71

PubMed: 32165861 ( click the link to review the publication )

Theranostics, 2020, 10(7):3351-3365

PubMed: 32194873 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:65

PubMed: 32158355 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4529

PubMed: 31586101 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Autophagy, 2019, 15(6):1100-1111

PubMed: 30654687 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

FASEB J, 2019, 33(12):13476-13491

PubMed: 31570001 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(16):2738-2751

PubMed: 31087038 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz152

PubMed: 31518391 ( click the link to review the publication )

Eur J Pharm Biopharm, 2019, 136:156-163

PubMed: 30682492 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Cancer Commun (Lond), 2019, 39(1):81

PubMed: 31796105 ( click the link to review the publication )

Eur J Pharmacol, 2019, 852:42-50

PubMed: 30851271 ( click the link to review the publication )

J Oncol, 2019, 2019:1805841

PubMed: 31275377 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2509-2517

PubMed: 31402948 ( click the link to review the publication )
Anticancer Res, 2019, 39(12):6731-6741

PubMed: 31810938 ( click the link to review the publication )

Mol Imaging, 2019, 18:1536012119870899

PubMed: 31478435 ( click the link to review the publication )

Pharmaceutics, 2019, 11(8)E401

PubMed: 31405159 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(10):1203-1214

PubMed: 30202050 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2494

PubMed: 29950602 ( click the link to review the publication )

Genome Res, 2018, 28(8):1207-1216

PubMed: 29898900 ( click the link to review the publication )

Cancer Res, 2018, 78(23):6632-6642

PubMed: 30322863 ( click the link to review the publication )

J Control Release, 2018, 269:245-257

PubMed: 29162480 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 433:210-220

PubMed: 30008386 ( click the link to review the publication )

Mol Pharm, 2018, 15(2):609-618

PubMed: 29308904 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):777-790

PubMed: 29431617 ( click the link to review the publication )

Sci Rep, 2018, 8(1):7222

PubMed: 29740146 ( click the link to review the publication )

Int J Oncol, 2018, 52(1):295-304

PubMed: 29115581 ( click the link to review the publication )

Cell Cycle, 2018, 17(10):1199-1211

PubMed: 29886801 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1404-1415

PubMed: 29479863 ( click the link to review the publication )

J Pharm Sci, 2018, 107(3):922-933

PubMed: 29162424 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:7031-7040

PubMed: 30410360 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5607-5614

PubMed: 30344715 ( click the link to review the publication )

Medicines (Basel), 2018, 5(2)

PubMed: 29925764 ( click the link to review the publication )

J Neurooncol, 2018,

PubMed: 29564747 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):523-535

PubMed: 27440269 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(20):6239-6253

PubMed: 28698200 ( click the link to review the publication )
Neuro Oncol, 2017, 20(2):236-248

PubMed: 29016925 ( click the link to review the publication )

Cell Syst, 2017, 4(6-:600-610

PubMed: 28601558 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Oncol, 2017, 11(2):180-193

PubMed: 28098415 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4375-4387

PubMed: 28973155 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:691-702

PubMed: 27823879 ( click the link to review the publication )

Oncotarget, 2017, 8(12):18626-18639

PubMed: 28148893 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29865-29886

PubMed: 28415741 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(9):2282-2292

PubMed: 28687190 ( click the link to review the publication )

JCI Insight, 2017, 2(24)

PubMed: 29263302 ( click the link to review the publication )

J Clin Invest, 2016, 126(5):1801-14

PubMed: 27043280 ( click the link to review the publication )

Cancer Res, 2016, 76(1):139-49

PubMed: 26542214 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Eur J Pharm Biopharm, 2016, 104:7-18

PubMed: 27106606 ( click the link to review the publication )

Neurochem Res, 2016, 41(12):3192-3205

PubMed: 27632183 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41251-41264

PubMed: 27183910 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69961-69975

PubMed: 27564106 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79869-79884

PubMed: 27829215 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):11443-56

PubMed: 27006309 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):467-72

PubMed: 26163089 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142704

PubMed: 26571493 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1555-65

PubMed: 24501391 ( click the link to review the publication )
Cancer Biol Ther, 2014, 15(12):1646-57

PubMed: 25482938 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(7):1740-7

PubMed: 23406775 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Features

Methazolastone is a second-generation alkylating agent.

Targets

DNA replication ^[1]
(L-1210, L-1210/BCNU cells)

In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.^[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. ^[2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. ^[3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. ^[4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Kelly	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWfEcJNRPDhiaB?=		M3nGfmlEPTB;MUO5MlIx6oDLwsJihKk2Njl3IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
KellyCis83	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUm0PEBp		NIf6OYhKSzVyPUK1NU4xOOLCidMx5qCKOTVwN{Wg{txO	NUTLTWpjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
SK-N-AS	NXLCSWN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3zYOlQ5KGh?		M{HVWGlEPTB;MkK3Mlcx6oDLwsJihKkzOi5zNTFOwG0>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
SK-N-ASCis24	NIPJfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV:0PEBp		NF\ES3VKSzVyPUS4NE43OOLCidMx5qCKOTBzLkG1JO69VQ>?	NWS4e4t[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
CHP-212	M4XNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYXFO49SPDhiaB?=		NV\ZS3Z4UUN3ME23Mlk46oDLwsJihKkxNjZ7IN88US=>	M{Dud\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
CHP-212Cis100	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEjabXc1QCCq		MV3JR\|UxRTlwNUZihKnDueLCiUCuPFgh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
U87	NEjFZ2VHfW6ldHnvckBCe3OjeR?=	NFfmdmQyODBizszN	MYiyOE04OiCq		NFvDcHBqdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?=	M3\xeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEC4PFY5Lz5{NUiwPFg3QDxxYU6=
LN229	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTBS4hKOC13MDFOwG0>			MUXJR\|UxRTF4IN88US=>	NFjCPHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1NFI4Oyd-MkW3OVAzPzN:L3G+
TR-LN229	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MViwMVUxKM7:TR?=			NV\4XllrUUN3ME23O{DPxE1?	NWTzdHlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVAzPzNpPkK1O\|UxOjd\|PD;hQi=>
U87	NHTsc2tCeG:ydH;zbZMhSXO\|YYm=	M{TEUVDjiJN{MEFihKnDvU1?	MYWyOEBp		Mn\q[Y5p[W6lZYOgR3EhcW6mdXPl[EBieG:ydH;zbZM>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MU[2PEc,OjV4OEG2Olg9N2F-
U251MG	MX7BdI9xfG:\|aYOgRZN{[Xl?	M4\uTVExOMLizszN	NHPtWoc1QCCq	MoDqVGJU	Mm\RbY5lfWOnczDhdI9xfG:\|aYO=	NGXOfXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NFQ3PCd-MkW2PFA1PjR:L3G+
U87MG	M2PIXmFxd3C2b4Ppd{BCe3OjeR?=	Mn\FNVAxyqEQvF2=	MWO0PEBp	M3q5ZnBDWw>?	M1zEbolv\HWlZYOgZZBweHSxc3nz	NGCwOnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NFQ3PCd-MkW2PFA1PjR:L3G+
U87	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofpOVAuOzVyIN88US=>	MYS0POKhcMLi		M2LGTYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6	Mof0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUSyNlMoRjJ3NUW0NlI{RC:jPh?=
U118	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX[1NE0{PTBizszN	NET6Rmo1QMLiaNMg		NIrOUm1qdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	NHvpUHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OFIzOyd-MkW1OVQzOjN:L3G+
U87	M{n2XWZ2dmO2aX;uJGF{e2G7	Mk\nNlUxNzN3MDFOwG0>	M3;LUVQ5yqCqwrC=		MnHZ[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm	NHvZUHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OFIzOyd-MkW1OVQzOjN:L3G+
U118	NEPF[HZHfW6ldHnvckBCe3OjeR?=	MmjpNlUxNzN3MDFOwG0>	MoroOFjDqGkEoB?=		NVfOXnM1\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn	MmrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUSyNlMoRjJ3NUW0NlI{RC:jPh?=
U87	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWSyOVAwOzVyIN88US=>	MknXOFjDqGkEoB?=		NH;RcYVqdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS\|IwVcLiY3;0doVifGWmIIfpeIghXE2[	M3\ySFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW0NlI{Lz5{NUW1OFIzOzxxYU6=
A375	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY[0POKhcMLi		NW\zNWFDUUN3ME2yOlUh\|ryP	MlfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
A2058	M2W3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2DDWFQ5yqCqwrC=		NUDvOppZUUN3ME2xNkDPxE1?	MmT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
M238	NX\LcGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVfR[Wp5PDkEoHlCpC=>		NWTnOIU1UUN3ME20NEDPxE1?	NGXmSHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyOFU2Oid-MkW1NlQ2PTJ:L3G+
M249	NYjXc5ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVTUfpNPPDkEoHlCpC=>		NITXSotKSzVyPUK1OEDPxE1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{NEW1Nkc,OjV3MkS1OVI9N2F-
M21	NUXXUW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3HY[VQ5yqCqwrC=		NWLIOm82UUN3ME2yNlEh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{NEW1Nkc,OjV3MkS1OVI9N2F-
U251	MWfDfZRwfG:6aYT5JGF{e2G7	Ml:wNlAh\|ryPwrC=	MUe0POKhcMLi		NXr3R4Q4emWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=>	Mm\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{SzPFEoRjJ3NEO0N\|gyRC:jPh?=
LN229	NYPYZoVDS3m2b4TvfIl1gSCDc4PhfS=>	MYqyNEDPxE4EoB?=	M{TkSVQ5yqCqwrC=		MkDWdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W\|IH;mJINwdG:waXXzJIZwem2nZB?=	NUTESXdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|Q{QDFpPkK1OFM1OzhzPD;hQi=>
U373MG-LUC	M1uzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUe0N\|FyPzJiaB?=		NFznNIFKSzVyPk[wNEDPxE1?	NWi5[G5ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|E6PTNpPkK1OFMyQTV\|PD;hQi=>
U87	NFX4S4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXtNlUuOjByIN88US=>	NVLZNmJIPDkEoHlCpC=>		Ml7RbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEC3OFUoRjJ3NECwO\|Q2RC:jPh?=
U251	NYrKeVhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrpeoczPS1{MECg{txO	MXq0POKhcMLi		Mnm4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NEnlTlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSwNFc1PSd-MkW0NFA4PDV:L3G+
U251	M2DW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\JVWoyODBvNECwJO69VQ>?	NVHzW4JpPzJxOU[gbC=>		M2TDTpRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?=	MknxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|N{WyO\|EoRjJ3M{e1NlcyRC:jPh?=
U373	NUSyS21xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlSwNVAxNTRyMDFOwG0>	NWfRR5VYPzJxOU[gbC=>		M{PYeJRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?=	NW\xTJdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO\|UzPzFpPkK1N\|c2OjdzPD;hQi=>
U343	Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH76NpcyODBvNECwJO69VQ>?	Mn3QO\|IwQTZiaB?=		NXiyZmZQfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg	NHTvTmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3OVI4OSd-MkWzO\|UzPzF:L3G+
U87MG-luc2	Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mki2NVAxNTRyMDFOwG0>	M1rHS\|czNzl4IHi=		MYP0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:\|c4nwc4wh\W6qYX7j[YQhyqB?	NIHMVnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3OVI4OSd-MkWzO\|UzPzF:L3G+
U87	NIjNV3hHfW6ldHnvckBCe3OjeR?=	MnLhNlAxKM7:TR?=	M1nsWVQ5KGh?		NEXocXNqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w	NV\SVmRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
U251	NVzLOIxXTnWwY4Tpc44hSXO\|YYm=	M1LKRlIxOCEQvF2=	NX;a[mRTPDhiaB?=		M4P1VIlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25?	M1jIO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O\|IyLz5{NUOzO\|czOTxxYU6=
A172	MlvzSpVv[3Srb36gRZN{[Xl?	MlTDNlAxKM7:TR?=	MVK0PEBp		M1fWS4lv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25?	MoDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{e3NlEoRjJ3M{O3O\|IyRC:jPh?=
U251	MnLvSpVv[3Srb36gRZN{[Xl?	MmSxNlAxKM7:TR?=	M3vCdVQ5KGh?		NGLDUW1qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{	MoP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{e3NlEoRjJ3M{O3O\|IyRC:jPh?=
A172	MmrsSpVv[3Srb36gRZN{[Xl?	MWOyNFAh\|ryP	NXTIXWI6PDhiaB?=		MlzubY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>?	NUD0blVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
U87	M1ruVmZ2dmO2aX;uJGF{e2G7	M{nLc\|IxOCEQvF2=	M2T1TFI1Nzd{L{GyNEBp		MWjpcoNz\WG\|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk>	NVHqb4E3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
U251	MkHkSpVv[3Srb36gRZN{[Xl?	NFXvfFQzODBizszN	M3TtU\|I1Nzd{L{GyNEBp		NEfZNpBqdmO{ZXHz[ZMh\|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl?	M3HzbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O\|IyLz5{NUOzO\|czOTxxYU6=
A172	Mmq1SpVv[3Srb36gRZN{[Xl?	MWeyNFAh\|ryP	M1nvTFI1Nzd{L{GyNEBp		NHfBTplqdmO{ZXHz[ZMh\|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl?	NUCxTVJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
SNB19V	NEP2[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2fZbVch\A>?	Mnv2SG1UVw>?	NVjXeFJ7T0l3ME2zOU44yrFzMjFOwG0>	Moi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
SNB19M	NHu0W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NETNSpo4KGR?	MV\EUXNQ	MXTHTVUxRTR4OT65xtE5QCEQvF2=	MmLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
SNB19VR	M2DBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGXZZlY4KGR?	MYHEUXNQ	MnzVS2k2OD1{OECuNuKyOThizszN	M1W5Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
U373V	NUDzN\|NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGX4cWQ4KGR?	M1OzOmROW09?	M3rmUmdKPTB;NkiuNOKyOzJizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
U373M	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1iwUVch\A>?	NYCzV\|huTE2VTx?=	M13jcmdKPTB;M{[4MlfDuTh4IN88US=>	MonpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
U373VR	NYXvSZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NU\BSWxbPyCm	NYnsOng4TE2VTx?=	MXTHTVUxRTJ6OD64xtE{OyEQvF2=	Ml;6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
U87MG	NIjsVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NY\PdWtWPyCm	NX\RRlh4TE2VTx?=	MYfHTVUxRTN6LkRCtVIxKM7:TR?=	Mm\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
HCT116	NFTEZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmLsO{Bl	NWmzfI1yTE2VTx?=	MVrHTVUxRTV5OT65xtE{OiEQvF2=	NE\SRnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
DLD1	NX\lW45VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIfpbGM4KGR?	MmKxSG1UVw>?	MV7HTVUxRTVyMT60xtE6OyEQvF2=	NYfkUIM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
MRC5	NH3CVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXm3JIQ>	MnnDSG1UVw>?	NEfIemRIUTVyPUS0PU41yrF6IN88US=>	NF2yfmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
SNB19V	M4DLU2Z2dmO2aX;uJGF{e2G7	M4X0S\|ExOCEQvF5CpHROYg>?	MorzNE04OiCq		M3XGOIlv[3KnYYPld{DPu0h{QWig[ZhxemW\|c3nvckBj\XS5ZXXuJFE3KGGwZDC3NkBp	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
T98G	MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\RN\|UwOTBxMUWg{txO	NFu5e\|QzPMLiaB?=		M1PJTYlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU	NYnUfpFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlI6PjFpPkK1NlYzQTZzPD;hQi=>
U251	NUKyOWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXO1M\|ExNzF3IN88US=>	MUOyOOKhcA>?		MU\pcoR2[2W\|IHPlcIwh\GWjdHig[I9{\S2mZYDlcoRmdnSueTDh[pRmeiClb37jc41qfGGwdD30[Y1wgm:ub33p[IUhf2m2aDDOVIU3NVCGVB?=	M2O3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[yPVYyLz5{NUK2Nlk3OTxxYU6=
T98G	MXXGeY5kfGmxbjDBd5NigQ>?	MWmxOUDPxE1?	MVmyOOKhcA>?		NYjKPXNMcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz	Mk\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
U251	M1O2W2Z2dmO2aX;uJGF{e2G7	M{XMNlE2KM7:TR?=	MknaNlTDqGh?		M2jEV4lv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?=	NHPkW409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2Nlk3OSd-MkWyOlI6PjF:L3G+
U-87 MG	MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2nF[FczKGh?		NHjBXpVKSzVyPUCuPVMhdU4EoB?=	NVHabm5[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFU{OzJpPkK1NlQ2OzN{PD;hQi=>
U-118 MG	NH:2N5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUnUXIo2PzJiaB?=		MkXqTWM2OD1zLkC1JI1OyqB?	NULEZm1URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFU{OzJpPkK1NlQ2OzN{PD;hQi=>
U87	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFrjPWkzPCCq		NVXMVGpOUUN3ME2yOlAvOzRizszNxsA>	M4X0S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUezNlM{Lz5{NUG3N\|I{OzxxYU6=
U87 GSLCs	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NITOOXozPCCq		NXLJO\|hKUUN3ME23OlYvOTFizszNxsA>	NFrYXHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3N\|I{Oyd-MkWxO\|MzOzN:L3G+
U87MG	MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2L0WFczKGh?		M{P0OGlEPTB;MUWuOlI2KM7:TdMg	NFzO[2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFkyPSd-MkWwOVA6OTV:L3G+
U251	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYGxNFAuPDByIN88US=>	MXe0PEBp	MnuySG1UVw>?	NXfF[45FcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M1nQRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO\|M3Lz5{NE[yN\|c{PjxxYU6=
U87	NHLLRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rsR\|ExOC12MECg{txO	M4TCRVQ5KGh?	M1jK[GROW09?	NYjMfoZYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M17xRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO\|M3Lz5{NE[yN\|c{PjxxYU6=
MDA-MB-231-br	NISyU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUKwMVExKM7:TR?=	MW[0PEBp	Mn3mSG1UVw>?	MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MonQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
HCC-1937	M1nmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjIXGsxNTNyMDFOwG0>	NX;VZZBLPDhiaB?=	NVPWW\|RkTE2VTx?=	Mln6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NU\INmJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlM4OzZpPkK0OlI{PzN4PD;hQi=>
MDA-MB-231	NVOwXYN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPlNE01OCEQvF2=	M1rySlQ5KGh?	M4DWbGROW09?	NH7ZfGdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MlHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
MDA-MB-468	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPxfVdzOC13MECg{txO	NE\O[m41QCCq	M2frO2ROW09?	M1PzSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N\|Y9N2F-
T47D	NVzKPXk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3Ke5gxNTFyMDFOwG0>	MkDLOFghcA>?	NGXJ[ZlFVVOR	MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	Mle1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
MCF7	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXuwMVExODBizszN	NVHySGZlPDhiaB?=	MUDEUXNQ	M4jXNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N\|Y9N2F-
Hs683	MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYOwMVExODBizszN	MX65OkBp		NITJeHdKSzVyPUGyPE46KM7:TR?=	MkTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUW5NFcoRjJ2NEm1PVA4RC:jPh?=
U87	NH3ScY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX:wMVExODBizszN	NXfYcXV[QTZiaB?=		MXjJR\|UxRTF6LkS1JO69VQ>?	M3LVdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1PVA4Lz5{NES5OVkxPzxxYU6=
LNZ308	NIjLZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonvNE0yODByIN88US=>	NXPON2hLQTZiaB?=		M2XPcGlEPTB;M{K2Mlch\|ryP	NEDK[m09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OVkxPyd-MkS0PVU6ODd:L3G+
U87	MVLBdI9xfG:\|aYOgRZN{[Xl?	MoL5NVAxKM7:TR?=	NXrveW4yPDhiaB?=	M1\jN2ROW09?	NYLkeJpwcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=>	NFP2TJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES4NVU5Pid-MkS0PFE2QDZ:L3G+
U251	M2H4V2Fxd3C2b4Ppd{BCe3OjeR?=	NHP6RogyODBizszN	NXLvPIxHPDhiaB?=	NWfLSmpjTE2VTx?=	MkDVbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?=	MnH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OEG1PFYoRjJ2NEixOVg3RC:jPh?=
U251	NWTRW4pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGLQeYkzPCCq		M4HsbWlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN	M2\TSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
U251	M{TpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXf0XFExPDhiaB?=		Mk\JTWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2=	NFPpflE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOlk2PCd-MkSzNlY6PTR:L3G+
U251	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlzJO\|IhcA>?		M4OwSGlEPTB;N{KuOFLjiIoEsfMAjVEvPDVizszN	M3[4U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
U251	M{Tvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGjW[HI6PiCq		M4jBfWlEPTB;NkmuPFLjiIoEsfMAjVMvODRizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{Nkm1OEc,OjR\|Mk[5OVQ9N2F-
T98G	M2fzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLuNE04PTBizszN	MoDGO\|IwQTZiaB?=		MkjQbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NXX4R45WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlQxQDBpPkK0N\|I1ODhyPD;hQi=>
U251-MG	MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nCfFAuQDByIN88US=>	NXj1dYRQPzJiaB?=		MoLxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	Mny5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO2N\|AoRjJ2MEmzOlMxRC:jPh?=
D54-MG	M1LyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH72UWcxNThyMDFOwG0>	NHntdlI4OiCq		Ml\KbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NXjGeZVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM3OzBpPkK0NFk{PjNyPD;hQi=>
SHG-44	M4LtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPwV3kyOC1{MECg{txO	MVO5OkBp		M3XhfGlEPTB;OT63N{DDuSB{LkGyJO69VQ>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
U373	M3LMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LYWlExNTJyMDFOwG0>	NIPIVYw6PiCq		M2rZ[2lEPTB;MUCuNVMhyrFiMT6wNkDPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
HT-29	MoH0SpVv[3Srb36gRZN{[Xl?	MWW1NFAh\|ryP	MofrNlQwPDhiaB?=		MXrlcohidmOnczD0bIUhdGW4ZXzzJI9nKM7\|LViyRXjDqA>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB\|OEC2PEc,OjRyM{iwOlg9N2F-
PC-3	NEHrTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjhXnQxNTJ3IN88US=>	M{TrWFQ5KGh?		M4XmRYlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDwc5RmdnSrYYTl[EBjgSCueXPvdIVv\Q>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2NkmzOEc,OjN5NE[5N\|Q9N2F-
PC-3	MUPBdI9xfG:\|aYOgRZN{[Xl?	Mne4NlUh\|ryP	NV;I[Hl6PDhiaB?=		NVrY[JpCcW6mdXPld{BieG:ydH;zbZMhf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m	NG\ib4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0Olk{PCd-MkO3OFY6OzR:L3G+
T98G	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HoTlUxNTRyMDFOwG0>	M{e5c\|E1PCCq		MVvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	Mk\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUW0PVkoRjJ\|N{G1OFk6RC:jPh?=
U87-MG	NV7BVohPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX2xNFAhyrWP	M3fZPVczKGh?		M1vQUIlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nke4PEc,OjN4OU[3PFg9N2F-
U251-MG	M3y5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3f0ZlExOCEEtV2=	MVW3NkBp		Mm\0bY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nke4PEc,OjN4OU[3PFg9N2F-
LNT-229	M3zGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU[zMVExOCEQvF2=	NEKxS3czPCCq		MUXpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1:xNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[3OlMzLz5{M{[2O\|Y{OjxxYU6=
T98G	NEnlfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETDcWQyOC15MECg{txO	MWmyOEBp		MVHpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MnjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke2N\|IoRjJ\|Nk[3OlMzRC:jPh?=
U87	MkGySpVv[3Srb36gRZN{[Xl?	MYixNFAhyrWP	NHixUIg{KGh?		NYXxRXM2\WyndnH0[ZMhfGinIHzleoVteyCxZjDwR4hsOSCjbnSgdGNpczJ?	M2KxTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[3OFY6Lz5{M{[2O\|Q3QTxxYU6=
HCT116	NUH4OJZJTnWwY4Tpc44hSXO\|YYm=	MknMNVAxKML3TR?=	NEHHcZY{KGh?		MX;pcoR2[2W\|IITo[UBEcGtzIGDoc5NxcG:{eXzheIlwdg>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4N{S2PUc,OjN4Nke0Olk9N2F-
HCT3-6	M2jMVmZ2dmO2aX;uJGF{e2G7	NFX6fpcyODBiwsXN	MXyzJIg>		MmjObY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25?	MoriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke0OlkoRjJ\|Nk[3OFY6RC:jPh?=
U-87	Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjuNE01OCEQvF2=	NGnDWpMyOiCm		MmL6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MlL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NEW3NlkoRjJ\|NkS1O\|I6RC:jPh?=
U-87	NHz6ZZRCeG:ydH;zbZMhSXO\|YYm=	M{X2S\|AuPDBizszN	Mm\wN{83KGR?		MnO4bY5lfWOnczDhdI9xfG:\|aYOgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NFrhU2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[0OVczQSd-MkO2OFU4Ojl:L3G+
U-87	M4KxZmZ2dmO2aX;uJGF{e2G7	MmPMNE01OCEQvF2=	NYTTV4FtOy94IHS=		M1izNIlv\HWlZYOgZZV1d3CqYXf5JIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
GB-SCC010	M4j2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHXweIg1KGR?		M4TyWmlEPTB;MkK2JO69VQ>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
GB-SCC026	M4nFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoHoOEBl		NXvpUJVbUUN3ME21N{4yKM7:TR?=	M4\OdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkGyO\|U2Lz5{M{[xNlc2PTxxYU6=
GB-SCC028	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn:5OEBl		MUPJR\|UxRTF4NzFOwG0>	M3;Ke\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkGyO\|U2Lz5{M{[xNlc2PTxxYU6=
U87	NFf4coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV;iVFFwPCCm		NHjaOGJKSzVyPUS1MlIh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
U87 stem cell	NWXIWWxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnS3OEBl		NHjER2ZKSzVyPU[2Mlch\|ryP	NUjuO4NURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVI4PTVpPkKzOlEzPzV3PD;hQi=>
TLX5 lymphoma	NFzGO3ZEgXSxdH;4bYNqfHliYYPzZZk>				MXLJR\|UxKD1iNTFOwG0>	M{LMXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd5M{mwNFgoRjd5M{mwNFg9N2F-
GM892 A	MXPDfZRwfG:6aXPpeJkh[XO\|YYm=				NHnVeHlKSzVyIE2gO{43KM7:TR?=	M4fwVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd5M{mwNFgoRjd5M{mwNFg9N2F-
TLX5 lymphoma	MXrDfZRwfG:6aXPpeJkh[XO\|YYm=				MojlTWM2OCB;IEWg{txO	M1z5OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NEW5NFE1Lz5zMkS1PVAyPDxxYU6=
HCT116	NILKdoxEgXSxdH;4bYNqfHliYYPzZZk>		MV60JIRigXN?		NHm1NWxKSzVyIE2gOE4{PCEQvF2=	NVXrbVlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NFA5ODNpPkG5PFAxQDB\|PD;hQi=>
SNB75	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	NU\Q[pA3OTBidV2=	MV[yOEBpenN?		M1LofmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU17CO\|Uh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEWyOkc,OjJ{Nki1NlY9N2F-
C6	NIXnZ4pCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	NEHOZmsyODBidV2=	MW[0PEBpenN?		NWHwcGJCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBz[XRiQ{[gZ4VtdHNiYYSgNVAxKHWPIHHmeIVzKDR6IHjyd{BjgSCwZYX0doFtKHKnZDDpcoNwenCxcnH0bY9vKGG\|c3H5	Mn\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{Nki1NlYoRjJ{Mk[4OVI3RC:jPh?=
SF295	M3zISGFvfGmycn;sbYZmemG2aY\lJIF{e2G7	MnrwNVAhfU1?	NFLoNpQzPCCqcoO=		M3i4c2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yPVUh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?=	NIjaZmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFUzPid-MkKyOlg2OjZ:L3G+
U87	NVXId2JQSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnO3OUBl[Xm\|		NInBbItKSzVyIE2gOFkh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZyOEO4PUc,OjJ4MEizPFk9N2F-
U138MG	NVHZTZVQS3m2b4TvfIlkcXS7IHHzd4F6		NIT3OGs1QCCqcoO=		MYDJR\|UxKD1iMk[g{txO	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4OU[4Nkc,OjNyNkm2PFI9N2F-
C6	NX76WHZIS3m2b4TvfIlkcXS7IHHzd4F6		MWS0PEBpenN?		MWXJR\|UxKD1iM{Sg{txO	NITydlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2PVY5Oid-MkOwOlk3QDJ:L3G+
A2780	NF3xXVlCdnSrdIXtc5Ih[XO\|YYm=		MUG1JIRigXN?		MljYTWM2OCB;IEiuOUDPxE1?	NGrKO3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i5OVYzOCd-MkO4PVU3OjB:L3G+
A2058	MkPxRY51cXS3bX;yJIF{e2G7		M{XOcFUh\GG7cx?=		M4PNdWlEPTBiPTCzOU42KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh7NU[yNEc,OjN6OUW2NlA9N2F-
SNB19	Mn\ORY51cXS3bX;yJIF{e2G7		MVW1JIRigXN?		NI\EcWNKSzVyIE2gN\|ch\|ryP	MkjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6OUW2NlAoRjJ\|OEm1OlIxRC:jPh?=
M8	MVTBdI9xfG:\|aYOgZZN{[Xl?	MX21NEB1dyBzMECgeW0>	NVj4U4dXPDhiaILz		NFPWTXpKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF24JINmdGy\|IHHzd4V{e2WmIHHzJIFxd3C2b4TpZ{9v\WO{b4TpZ{Bk\WyuczDheEA2OCC2bzCxNFAhfU1iYX\0[ZIhPDhiaILzJIJ6KEGSQz3sZYJmdGWmIHHucoV5cW5iVjDhcoQhPy2DQVSgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{	NWPJS2pzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlU5PzdpPkK0NVI2QDd5PD;hQi=>
SK-MEL-30	M4GxeGFxd3C2b4Ppd{Bie3OjeR?=	Mk\2NVAxKHWP	NVTzWmFGPDhiaILz		NXeyfmYzUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT{1OTUxvM{CgZ4VtdHNiYYPz[ZN{\WRiYYOgZZBweHSxdHnjM45m[3KxdHnjJINmdGy\|IHH0JFExOCC3TTDh[pRmeiB2ODDodpMh[nliQWDDMYxi[mWuZXSgZY5v\XirbjDWJIFv\CB5LVHBSEB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{NUi3O{c,OjRzMkW4O\|c9N2F-
SK-MEL-30	NWKwTJJkSXCxcITvd4l{KGG\|c3H5	M2DvR\|UxKHWP	MnHJOFghcHK\|		NXfBb45HUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT{1OTUxvM{CgZ4VtdHNiYYPz[ZN{\WRiYYOgZZBweHSxdHnjM45m[3KxdHnjJINmdGy\|IHH0JFUxKHWPIHHmeIVzKDR6IHjyd{BjgSCDUFOtcIFj\WynZDDhco5mgGmwIG[gZY5lKDdvQVHEJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyC{ZXzheIl3\SC2bzDjc451em:u	MlLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkW4O\|coRjJ2MUK1PFc4RC:jPh?=
MNT1	NUPZTmFbSXCxcITvd4l{KGG\|c3H5	MoXqNVAxKHWP	NIHPT3A1QCCqcoO=		NUXCbJE{UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNUnQyKGOnbHzzJIF{e2W\|c3XkJIF{KGGyb4D0c5Rq[y:wZXPyc5Rq[yClZXzsd{BifCBzMECgeW0h[W[2ZYKgOFghcHK\|IHL5JGFRSy2uYXLlcIVlKGGwbnX4bY4hXiCjbnSgO{1CSURic4ThbY5qdmdvYnHz[YQh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKGOxboTyc4w>	NHLvbFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
MNT1	MnWxRZBweHSxc3nzJIF{e2G7	NUXCZ\|JWPTBidV2=	MUG0PEBpenN?		M{e0PWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTV7UNUBk\WyuczDhd5Nme3OnZDDhd{BieG:ydH;0bYMwdmWlcn;0bYMh[2WubIOgZZQhPTBidV2gZYZ1\XJiNEigbJJ{KGK7IFHQR{1t[WKnbHXkJIFvdmW6aX6gWkBidmRiNz3BRWQhe3SjaX7pcocu[mG\|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|IILlcIF1cX[nIITvJINwdnS{b3y=	NWXrRZRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlU5PzdpPkK0NVI2QDd5PD;hQi=>
A2780	NHzDNWlEgXSxdH;4bYNqfHliYYPzZZk>		MYe1JIRigXN?		NU\MV\|U5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WVDDhd5NigQ>?	M134VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOFE5Lz5{NEmwNFQyQDxxYU6=
A2780/CP70	M1u2eWN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mn61OUBl[Xm\|		NIXhfZBEgXSxdH;4bYNqfHliYXfhbY5{fCCPTWKt[IVncWOrZX70JIh2dWGwIFGyO\|gxN0OSN{CgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WVDDhd5NigQ>?	M4\5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOFE5Lz5{NEmwNFQyQDxxYU6=
GBM 047T	M{S0cWFvfGm2dX3vdkBie3OjeR?=	MWeyNEB2VQ>?	NXzwNGJqOSC2bzCyJJdm\Wu\|		NWnMbVRyXHWvb4LpZ4ll[WxiZX\m[YN1KGmwIIDheIlmdnRiZHXybZZm\CCJQl2gNFQ4XCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gcoV2em:\|cHjldoUh\m:{bXH0bY9vKGG2IEKwJJVOKGGodHXyJFEhfG9iMjD3[YVseyCkeTCzSEB1fW2xcjDjcI9vd2enbnnjJIF{e2G7	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3NUWzNkc,OjZ\|NUW1N\|I9N2F-
GBM 464T	M1rZRWFvfGm2dX3vdkBie3OjeR?=	NYXGWIRpOjBidV2=	MX:xJJRwKDJid3Xlb5M>		M{DEWnR2dW:{aXPp[IFtKGWoZnXjeEBqdiCyYYTp[Y51KGSncnn2[YQhT0KPIES2OHQh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIH7leZJwe3CqZYLlJIZwem2jdHnvckBifCB{MDD1UUBi\nSncjCxJJRwKDJid3Xlb5Mh[nliM1SgeJVud3JiY3zvco9o\W6rYzDhd5NigQ>?	NXPw[pJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVU2OzJpPkK2N\|U2PTN{PD;hQi=>
U87MG	M4P1NWZ2dmO2aX;uJIF{e2G7		NHr4bm0{KGi{cx?=		NFPoW4hKdmS3Y4Tpc44hd2ZiRF7BJIFtc3muYYTpc44hcW5iaIXtZY4hXTh5TVegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hVjdvTXXkS{Bnd3KvYYTpc44h[W[2ZYKgN{BpenNiYomgUGMuVVNxTWOgZY5idHm\|aYO=	M3\pU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkG0OFE1Lz5{N{[xOFQyPDxxYU6=
U87MG	M4DGT2FvfGm2dX3vdkBie3OjeR?=				M4ThemFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJI9zfGixdH;wbYNidGy7IIjlco9oemGodHXkJIlvKEijcnzhckBvfWSnIH3veZNmKGK{YXnuJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDzcI94KHS3bX;yJIdzd3e2aDDheEA2OCC3bX;sM4toNCCrdjDh[I1qdmm\|dHXy[YQhd26lZTDkZYltgSCob4KgOUBl[Xm\|	NUnnNohKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
U87MG	NWHSRZV[SW62aYT1cY9zKGG\|c3H5				NH7jRXVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BwenSqb4TvdIlk[WyueTD4[Y5w\3KjZoTl[EBqdiCKYYLsZY4hdnWmZTDtc5V{\SCkcnHpckBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDtc5V{\SC\|dYL2bZZidCCjdDC1NEB2dW:uL3vnMEBqfiCjZH3pcol{fGW{ZXSgc45k\SCmYXnsfUBnd3JiNTDkZZl{	NFTR[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[xOFQyPCd-Mke2NVQ1OTR:L3G+
MDCK	MmH2R5l1d3SxeHnjbZR6KGG\|c3H5		MXGyOEBpenN?		MmT1R5l1d3SxeHnjbZR6KGGpYXnud5QhVUSFSzDj[YxteyCneIDy[ZN{cW6pIHPhdoJwdmmlIHHubJllemG\|ZTC5JIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDt[YF{fXKnZDDh[pRmeiB5IHThfZMhfW6mZYKgco9zdW:6aXOgZ49v\Gm2aX;uJIJ6KG2ndHj5cIVv\SCkbIXlJJN1[WmwaX7nJIJie2WmIHPsc45w\2WwaXOgd5Vzfmm4YXygZZN{[Xl?	Mo\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MkO4O\|koRjJ5OEKzPFc6RC:jPh?=
MDCK	MoHmR5l1d3SxeHnjbZR6KGG\|c3H5		MUKyOEBpenN?		MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBOTEONIHPlcIx{KGW6cILld5NqdmdiY3HyZo9vcWNiYX7ofYRz[XOnIEmgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgNlQhcHK\|IH3lZZN2emWmIHHmeIVzKDdiZHH5d{B2dmSncjDofZBwgGmlIHPvcoRqfGmxbjDifUBu\XSqeXzlcoUh[my3ZTDzeIFqdmmwZzDiZZNm\CClbH;uc4dmdmmlIIP1dpZqfmGuIHHzd4F6	NHTtSYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{iyN\|g4QSd-Mke4NlM5Pzl:L3G+
NB-EBc1	MYDxTHRUKGG\|c3H5				MnvrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	M{juUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
C6	NEnJWINEgXSxdH;4bYNqfHliYYPzZZk>		NVjkdWE3PCCmYYnz		NVnlV5J7TUN3MDC9JFE3NjVizszN	NYLl[Vh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>
U87	NXfDN2JZS3m2b4TvfIlkcXS7IHHzd4F6		NH;Rflg4OiCqcoO=		NWjESo85UUN3MDC9JFE6NjN6IN88US=>	NHnLOnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
SNB19	M1\COWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGD2d3M4KGSjeYO=		MYDHTVUxKD1iM{WuO{DPxE1?	M1;vSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=
SNB19	M13oO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUO3JIRigXN?		MWLHTVUxKD1iNEWuOkDPxE1?	MnixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=
U373	MXLGeY5kfGmxbjDhd5NigQ>?	M{nndFExOCC3TR?=	M1vDRlczKGi{cx?=		M1\XSmlv\HWldHnvckBw\iCmb4XicIUhe3S{YX7k[YQhTE6DIHLy[YFsKGmwIHXtdJR6KH[nY4TvdkB1emGwc3\lZ5Rm\CCqdX3hckBWOzd\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIdidW2jLViyRXghdGW4ZXygZZQhOTByIIXNJIFnfGW{IEeyJIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>?	NUT6VHRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>
Glioma	NV2ySIhVSW62aYT1cY9zKGG\|c3H5				NIrvfYZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBJd22xIIPhdIlmdnNiKHj1cYFvMSCJbHnvcYEh[2WubIOgfIVvd2e{YX\0[YQhcW5idILhcpNo\W6rYzDtc5V{\SCjc4Pld5Nm\CCjczDtc5V{\SC\|dYL2bZZidA>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4NVAwLz6FaFXNRmw9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pERK / ERK / p-p38 / p38; PubMed: 24436439 Stem Cells Transl Med Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression. DR5 / c-FLIP / Survivin / XIAP; PubMed: 24436439 Stem Cells Transl Med Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours.	24436439
Growth inhibition assay	Cell viability; PubMed: 25751281 Mol Pharm Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.	25751281
Immunofluorescence	Phalloidin / Phospho-H2A.X; PubMed: 27375225 Sci Rep Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). cleaved caspase-3; PubMed: 25663820 Cancer Cell Int Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).	27375225 25663820

In vivo

After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. ^[1]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: L-1210 and L-1210/BCNU cells
Concentrations: 0 μM -100 μM
Incubation Time: l hours
Method:
L-1210 and L-1210/BCNU cells are seeded at 0.2 × 10₄ cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 10₅ and 8 × 10₅/mL. Control growth is logarithmic in this range.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
Dosages: 40 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	38 mg/mL (195.72 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Temozolomide SDF

Molecular Weight	194.15
Formula	C₆H₆N₆O₂
CAS No.	85622-93-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CCRG81045, NSC 362856,TMZ
Smiles	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04610736	Not yet recruiting	Drug: Temozolomide Oral Suspension	Pediatric Cancer	Orphelia Pharma\|ClinSearch	January 2021	Phase 1
NCT04514393	Not yet recruiting	Drug: Methotrexate\|Drug: Ibrutinib\|Drug: Temozolomide	Primary Central Nervous System Lymphoma\|PCNSL\|Non Hodgkin Lymphoma	Huiqiang Huang\|Guangdong 999 Brain Hospital\|Nanfang Hospital of Southern Medical University\|Xian-Janssen Pharmaceutical Ltd.\|Sun Yat-sen University	December 1 2020	Phase 2
NCT04238819	Recruiting	Drug: Abemaciclib\|Drug: Irinotecan\|Drug: Temozolomide	Relapsed Solid Tumor\|Refractory Solid Tumor	Eli Lilly and Company	November 9 2020	Phase 1
NCT03796507	Not yet recruiting	Drug: Temozolomide	Glioma of Brain	University of Rochester\|National Institutes of Health (NIH)	September 1 2020	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
YK-4-279 ^New

YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
Cisplatin

Cisplatin (cisplatinum, cis-diamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine HCl

Gemcitabine HCl (LY188011) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Oxaliplatin

Oxaliplatin (L-OHP) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Bleomycin Sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Fluorouracil (5-Fluorouracil, 5-FU)

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Carboplatin

Carboplatin (JM-8, CBDCA, NSC 241240) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Features:A DNA synthesis inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Temozolomide